31 Jul 2024
To date, the National and Kapodistrian University of Athens (NKUA) has collected blood samples from 287 newly diagnosed patients of 9 different types of hematological malignancies. More specifically, for stage one, 188 blood samples have been sent to Tel Aviv University (TAU) to be used for the development of the HemaChip.
Moreover, the same team is working on periodically collecting and processing blood samples from subjects with a high risk of relapse or disease progression (acute myeloid leukemia, lymphoma, and multiple myeloma). In concordance with that, since the SANGUINE team has reached the final recruitment goal for monoclonal gammopathy of undetermined significance (MGUS) patients, the NKUA team continues to collect blood samples from newly diagnosed MGUS patients (107 subjects) and process their samples on site. This procedure includes the genomic DNA and Cell Free DNA extraction from patients’ samples, along with the final separation and freezing of the plasma and buffy coat.
In the next step, these bio-samples from follow-up or new MGUS patients will be used to test the HemaChip, once it is developed and delivered to NKUA. Regarding this stage, the NKUA team has been trained on the use of InnoScan 910, “Innopsys”, which is the microarray scanner that will be used to validate the HemaChip against the current Standard of Care (SOC) diagnostic tools and measures, as an early hint during the screening and monitoring of hematological malignancies.